UCB’s fast-growing Bimzelx leaps across blockbuster sales threshold as HS momentum builds
After UCB’s Bimzelx scored five approvals in just two years, the Belgian drugmaker has quickly made a blockbuster out of its up-and-coming immunology powerhouse. As the first med to selectively inhibit IL-17F as well as IL-17A, Bimzelx entered the crowded plaque psoriasis arena in 2023 before tacking on indications the following year in active psoriatic […]
One in Three Rheumatologists View BMS’ Sotyktu as a Substantial Advance in Psoriatic Arthritis Ahead of March 6 FDA Decision, According to Spherix Global Insights Data
Findings show strong pre-launch awareness, safety-driven TYK2 differentiation from JAK inhibitors, and opportunity for Bristol Myers Squibb to strengthen rheumatology standing. EXTON, PA — February 27, 2026 — With the FDA’s March 6, 2026 PDUFA date approaching for Sotyktu (deucravacitinib) in psoriatic arthritis (PsA), new findings from RealTime Dynamix™: Psoriatic Arthritis Q1 (US), show that U.S. rheumatologists are actively monitoring the potential approval. Sotyktu, an oral selective […]
Novo Nordisk’s Wegovy® Pill Achieves Strong First-Month Uptake, Signaling Expanding Demand for Oral GLP-1s in Obesity
Awareness and prescribing of the Wegovy pill for weight loss surge among primary care physicians and endocrinologists following its January launch. Exton, PA, February 20, 2026 – The obesity treatment landscape continues to evolve rapidly as demand for GLP-1–based therapies remains strong and competition intensifies. Novo Nordisk’s December 2025 FDA approval of Wegovy® (semaglutide), the […]
Gazyva Establishes Early Clinical Credibility in Lupus Nephritis Three Months Post-Approval, According to Spherix Global Insights
Initial uptake reflects strong efficacy-driven positioning relative to established therapies, though familiarity gaps, payer controls, and measured promotional visibility shape the pace of adoption. EXTON, PA – February 17, 2026 – Three months into its U.S. launch for lupus nephritis (LN), Roche/Genentech’s Gazyva (obinutuzumab) is entering a treatment landscape shaped not only by approved agents […]